BioCentury | May 18, 2015
Strategy

Alexion executes

...kinase company Blueprint Medicines Corp. , PPD LLC's X-chem Inc. subsidiary and macrocycle company Ensemble Therapeutics Corp....
...and Institutions Mentioned Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Blueprint Medicines Corp. (NASDAQ:BPMC), Cambridge, Mass. Ensemble Therapeutics Corp....
BioCentury | Apr 2, 2015
Distillery Therapeutics

Therapeutics: Baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); X-linked inhibitor of apoptosis (XIAP)

...B. et al. J. Med. Chem.; published online Feb. 19, 2015 doi:10.1021/jm501892g CONTACT: Nick Terrett, Ensemble Therapeutics Corp....
BioCentury | Aug 21, 2014
Tools & Techniques

Circling back to basics

...of the new macrocycle startup Circle Pharma Inc. Nick Terrett, CSO of synthetic macrocycle company Ensemble Therapeutics Corp....
...NASDAQ:BIIB), Weston, Mass. Boston University , Boston, Mass. Circle Pharma Inc. , San Francisco, Calif. Ensemble Therapeutics Corp....
BioCentury | Aug 18, 2014
Finance

Flagship's fashion

...Moderna and Pronutria , other therapeutic companies out of VentureLabs include Syros Pharmaceuticals Inc. and Ensemble Therapeutics Corp....
...Inc. (NASDAQ:CNCE), Lexington, Mass. Editas Medicine , Cambridge, Mass. Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Ensemble Therapeutics Corp....
BioCentury | Apr 14, 2014
Company News

Deciphera management update

...Kan. Business: Cancer Hired: Michael Taylor as president, CEO and a director, formerly CEO of Ensemble Therapeutics Corp....
BioCentury | Feb 24, 2014
Tools & Techniques

Bigger is better

...magnitude larger than DNA-encoded chemical libraries constructed with competing platforms, such as those used by Ensemble Therapeutics Corp....
...Companies and Institutions Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Bayer AG (Xetra:BAYN), Leverkusen, Germany Ensemble Therapeutics Corp....
BioCentury | Aug 15, 2013
Targets & Mechanisms

IL-17 inhibitors: good news, bad news

...Covagen AG COVA322 IL-17A and tumor necrosis factor (TNF) Protein Preclinical to treat inflammatory diseases Ensemble Therapeutics Corp./Novartis...
BioCentury | Aug 12, 2013
Company News

Ensemble Therapeutics, Novartis deal

...has six major partnerships involving its Ensemblin technology. Ensemblins are orally available synthetic macrocyclic compounds. Ensemble Therapeutics Corp....
BioCentury | Aug 7, 2013
Top Story

Ensemble licenses IL-17 program to Novartis

Ensemble Therapeutics Corp. (Cambridge, Mass.) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to its lead program of small molecule macrocyclic antagonists of IL-17A identified using Ensemble's Ensemblin technology. The oral compounds are in preclinical...
BioCentury | Jul 22, 2013
Company News

Alexion, Ensemble Therapeutics deal

...York, N.Y.) and Pfizer Inc. (NYSE:PFE, New York, N.Y.). Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Ensemble Therapeutics Corp....
Items per page:
1 - 10 of 44
BioCentury | May 18, 2015
Strategy

Alexion executes

...kinase company Blueprint Medicines Corp. , PPD LLC's X-chem Inc. subsidiary and macrocycle company Ensemble Therapeutics Corp....
...and Institutions Mentioned Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Blueprint Medicines Corp. (NASDAQ:BPMC), Cambridge, Mass. Ensemble Therapeutics Corp....
BioCentury | Apr 2, 2015
Distillery Therapeutics

Therapeutics: Baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); X-linked inhibitor of apoptosis (XIAP)

...B. et al. J. Med. Chem.; published online Feb. 19, 2015 doi:10.1021/jm501892g CONTACT: Nick Terrett, Ensemble Therapeutics Corp....
BioCentury | Aug 21, 2014
Tools & Techniques

Circling back to basics

...of the new macrocycle startup Circle Pharma Inc. Nick Terrett, CSO of synthetic macrocycle company Ensemble Therapeutics Corp....
...NASDAQ:BIIB), Weston, Mass. Boston University , Boston, Mass. Circle Pharma Inc. , San Francisco, Calif. Ensemble Therapeutics Corp....
BioCentury | Aug 18, 2014
Finance

Flagship's fashion

...Moderna and Pronutria , other therapeutic companies out of VentureLabs include Syros Pharmaceuticals Inc. and Ensemble Therapeutics Corp....
...Inc. (NASDAQ:CNCE), Lexington, Mass. Editas Medicine , Cambridge, Mass. Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Ensemble Therapeutics Corp....
BioCentury | Apr 14, 2014
Company News

Deciphera management update

...Kan. Business: Cancer Hired: Michael Taylor as president, CEO and a director, formerly CEO of Ensemble Therapeutics Corp....
BioCentury | Feb 24, 2014
Tools & Techniques

Bigger is better

...magnitude larger than DNA-encoded chemical libraries constructed with competing platforms, such as those used by Ensemble Therapeutics Corp....
...Companies and Institutions Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Bayer AG (Xetra:BAYN), Leverkusen, Germany Ensemble Therapeutics Corp....
BioCentury | Aug 15, 2013
Targets & Mechanisms

IL-17 inhibitors: good news, bad news

...Covagen AG COVA322 IL-17A and tumor necrosis factor (TNF) Protein Preclinical to treat inflammatory diseases Ensemble Therapeutics Corp./Novartis...
BioCentury | Aug 12, 2013
Company News

Ensemble Therapeutics, Novartis deal

...has six major partnerships involving its Ensemblin technology. Ensemblins are orally available synthetic macrocyclic compounds. Ensemble Therapeutics Corp....
BioCentury | Aug 7, 2013
Top Story

Ensemble licenses IL-17 program to Novartis

Ensemble Therapeutics Corp. (Cambridge, Mass.) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to its lead program of small molecule macrocyclic antagonists of IL-17A identified using Ensemble's Ensemblin technology. The oral compounds are in preclinical...
BioCentury | Jul 22, 2013
Company News

Alexion, Ensemble Therapeutics deal

...York, N.Y.) and Pfizer Inc. (NYSE:PFE, New York, N.Y.). Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Ensemble Therapeutics Corp....
Items per page:
1 - 10 of 44